Navigation Links
Jazz Pharmaceuticals Announces Stockholder Vote in Favor of Transaction With Azur Pharma Limted
Date:12/12/2011

e proposed transaction; disruption from the proposed transaction, making it more difficult to conduct business as usual or maintain relationships with customers, employees or suppliers; the allocation of the acquisition price to the net assets acquired in accordance with applicable accounting rules and methodologies; and the possibility that if the combined company does not achieve the perceived benefits of the proposed transaction as rapidly or to the extent anticipated by financial analysts or investors, the market price of the combined company's shares could decline, as well as other risks related to Jazz Pharmaceuticals' business, including Jazz Pharmaceuticals' dependence on sales of Xyrem and its ability to increase sales of its Xyrem and Luvox CR products; competition, including potential generic competition; Jazz Pharmaceuticals' dependence on single source suppliers and manufacturers; the ability of Jazz Pharmaceuticals to protect its intellectual property and defend its patents; regulatory obligations and oversight; Jazz Pharmaceuticals' cash flow; and those other risks related to Jazz Pharmaceuticals, Inc. and Jazz Pharmaceuticals plc after the closing detailed from time-to-time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals' SEC filings and reports, including in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2011 and, with respect to risks related to Jazz Pharmaceuticals plc after the closing, in Jazz Pharmaceuticals' definitive proxy statement related to its stockholders' meeting held on December 12, 2011. Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.


'/>"/>
SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... According to a new market ... (Endoscopes, Endoscopic Operative Devices, and Visualization Systems) - Global ... the global endoscopy devices market was valued at USD ... at a CAGR of 6.8% from 2013 to 2019, ... in 2019. Browse the full Endoscopy Devices Market ...
(Date:7/10/2014)... India , July 11, 2014  Major ... treatment of cancer are being highlighted in a ... Mumbai from 10-12 July, 2014.  Renowned national ... to share best practices and exchange knowledge on ... precise, accurate and efficient. The ...
(Date:7/10/2014)... SAN DIEGO , July 10, 2014  RESMED INC. ... report its fourth quarter and fiscal year ended June 30, ... York Stock Exchange market close. A press release with ResMed,s ... and the company will host a webcast to discuss operating ... scheduled to begin at 1:30 p.m. US Pacific Time and ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... AVIV, Israel, May 6 InspireMD, developers of,MGuard(TM), announced ... the,iMOS registry. MGuard(TM) was successfully implanted at the General,University ... Jan Horak. , InspireMD plans ... is a post market study, will be conducted in ...
... - Conference Call Today at 5:00 p.m. Eastern Time ... Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical ... the first quarter ended March 31, 2009, and provided ... pivotal Phase 3 SPEAR trial of picoplatin for the ...
Cached Medicine Technology:InspireMD Announces the Enrollment of the 1st Patient in the MGuard iMOS Registry, the Registry Will Enroll 1000 Patients 2InspireMD Announces the Enrollment of the 1st Patient in the MGuard iMOS Registry, the Registry Will Enroll 1000 Patients 3Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 2Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 3Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 4Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 5Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 6Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 7Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 8Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 9
(Date:7/11/2014)... (PRWEB) July 11, 2014 Recently, iFitDress.com, ... special occasion outfits, has released its new collection of ... that, the company has announced that all these beautiful ... off. The deadline of the special offer is July ... its major officials pay close attention to customer satisfaction. ...
(Date:7/11/2014)... Organic Crop Farming in ... the limelight over the past decade. According to IBISWorld ... to be an alternative food eaten only by minority ... organic food.” Organic crop farmers have reaped the benefits ... and herbs over the past five years. Industry revenue ...
(Date:7/11/2014)... era of personalized medicine may be just around the ... researcher Min Yu and scientists at Massachusetts General Hospital ... study in Science , Yu and her colleagues ... the blood streams of six patients. Some of these ... travel to and establish secondary tumors in vital organs ...
(Date:7/11/2014)... Alliance Labs announced that they will be featured ... Jr, airing later this year 2014, via Discovery Channel. ... Innovations will explore DocuSol® Kids, a mini-enema containing a ... base designed to give adolescents general constipation relief. Viewers ... hyperosmotic laxative by drawing water into the bowel from ...
(Date:7/11/2014)... Cruciate Ligament (ACL) reconstructions occur more than 200,000 times ... create a new ligament may determine how long you ... today at the Annual Meeting of the American Orthopaedic ... study results highlight that in a young athletic population, ... than using autografts (tissue harvested from the patient)," said ...
Breaking Medicine News(10 mins):Health News:Worldwide Chic Ladies Can Buy Cheap Evening Dresses at iFitDress.com 2Health News:Organic Crop Farming in Australia Industry Market Research Report Now Available from IBISWorld 2Health News:Organic Crop Farming in Australia Industry Market Research Report Now Available from IBISWorld 3Health News:Organic Crop Farming in Australia Industry Market Research Report Now Available from IBISWorld 4Health News:Alliance Labs & DocuSol® to be Featured in Upcoming Episode of Innovations 2Health News:ACL reconstructions may last longer with autografts 2
... efforts to unlock therapeutic potential , , MONDAY, Feb. 9 ... Obama,s anticipated lifting of the eight-year ban on embryonic ... W. Bush. , The anticipation moved one step closer ... House Democrats at a closed-door Virginia retreat a "guarantee" ...
... Inc. (Nasdaq: BNVI ) announced today the ... company,s Scientific Advisory Board. Dr. Gustafsson has extensive experience ... biotech companies. "We are very excited to have Dr. ... advancing our discovery platforms," said Isaac Cohen, O.M.D., Bionovo,s ...
... Fla., Feb. 9 MEDai, Inc., a leading provider ... it is offering a free case study on its ... analytic solution Risk Navigator Clinical(R) and its,application to keep ... The case study explores how one of MEDai,s ...
... -- Mindray Medical,International Limited (NYSE: MR ... devices worldwide, today announced that it will report ... year ended December 31,2008, after the U.S. market ... an earnings conference call at 8:00 AM on ...
... during 2008 holiday shopping seasonFORT WORTH, Texas, Feb. 9 ... customers, raised nearly $1.5 million for the fifth-annual ... fundraising initiative for St. Jude Children,s Research Hospital that ... , Customers who shopped at RadioShack stores had the ...
... supplement is the real deal. Extreme Endurance is a 100% ... certified drug-free by the world,s largest sports drug laboratory. In a ... lactic acid was reduced by 15%. This was a 30 day ... ...
Cached Medicine News:Health News:Scientists Heartened at Prospect of End to Stem Cell Ban 2Health News:Scientists Heartened at Prospect of End to Stem Cell Ban 3Health News:Jan Ake Gustafsson, M.D., Ph.D., Joins Bionovo's Scientific Advisory Board 2Health News:Jan Ake Gustafsson, M.D., Ph.D., Joins Bionovo's Scientific Advisory Board 3Health News:Jan Ake Gustafsson, M.D., Ph.D., Joins Bionovo's Scientific Advisory Board 4Health News:Health Plans Use MEDai to Forecast, Rank Risk and Drive Interventions 2Health News:Mindray to Report Fourth Quarter and Fiscal Year 2008 Financial Results on March 4, 2009 2Health News:RadioShack Helps Raise $1.5 Million for St. Jude Children's Research Hospital(R) Fifth-Annual Thanks and Giving(R) Campaign 2Health News:RadioShack Helps Raise $1.5 Million for St. Jude Children's Research Hospital(R) Fifth-Annual Thanks and Giving(R) Campaign 3Health News:Nutritionist Investigates Claims of New Sports Nutritional Supplement 2Health News:Nutritionist Investigates Claims of New Sports Nutritional Supplement 3Health News:Nutritionist Investigates Claims of New Sports Nutritional Supplement 4Health News:Nutritionist Investigates Claims of New Sports Nutritional Supplement 5
Shepard tying forceps, round curved platform 8 mm, 8.5 cm....
Girard curved tying forceps made of titanium has curved shafts with 8 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 99 mm....
Girard straight tying forceps made of titanium has straight shafts with 6 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 105 mm....
Curved tying forceps made of titanium has curved shafts with 6 mm V-grove tying platforms, width of shafts 0,5 mm, TCI platforms, flat handle, width 10 mm, overall length 103 mm....
Medicine Products: